Patents by Inventor Arvind Rajpal
Arvind Rajpal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220175921Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Patent number: 11338035Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: GrantFiled: April 13, 2020Date of Patent: May 24, 2022Assignee: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 11312782Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: April 15, 2019Date of Patent: April 26, 2022Assignee: Pfizer Inc.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Patent number: 11306150Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.Type: GrantFiled: January 10, 2018Date of Patent: April 19, 2022Assignees: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
-
Publication number: 20220073617Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: July 10, 2019Publication date: March 10, 2022Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
-
Publication number: 20220033462Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.Type: ApplicationFiled: July 26, 2021Publication date: February 3, 2022Applicants: ALLOGENE THERAPEUTICS, INC., CELLECTISInventors: ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
-
Publication number: 20220002428Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: July 13, 2021Publication date: January 6, 2022Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG
-
Patent number: 11213586Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: November 17, 2016Date of Patent: January 4, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Haichun Huang, Susan Chien-Szu Wong, Huiming Li, Bryan C. Barnhart, Aaron P. Yamniuk, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
-
Patent number: 11155630Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.Type: GrantFiled: December 21, 2020Date of Patent: October 26, 2021Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
-
Patent number: 11091544Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: September 7, 2018Date of Patent: August 17, 2021Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 11072644Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.Type: GrantFiled: November 9, 2015Date of Patent: July 27, 2021Assignees: Allogene Therapeutics, Inc., CellectisInventors: Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
-
Publication number: 20210188991Abstract: The present invention relates bispecific antibodies that specific binds to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.Type: ApplicationFiled: December 21, 2020Publication date: June 24, 2021Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Patent number: 11014989Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.Type: GrantFiled: January 25, 2016Date of Patent: May 25, 2021Assignee: CellectisInventors: Julianne Smith, Julien Valton, Alexandre Juillerat, Philippe Duchateau, Barbra Johnson Sasu, Arvind Rajpal
-
Publication number: 20210115159Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: ApplicationFiled: November 18, 2020Publication date: April 22, 2021Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
-
Patent number: 10941216Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: GrantFiled: May 11, 2017Date of Patent: March 9, 2021Assignee: Pfizer Inc.Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
-
Publication number: 20210054087Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: August 27, 2020Publication date: February 25, 2021Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20210017283Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: March 19, 2019Publication date: January 21, 2021Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Publication number: 20200368349Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: ApplicationFiled: April 13, 2020Publication date: November 26, 2020Applicant: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 10793635Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: GrantFiled: June 25, 2018Date of Patent: October 6, 2020Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
-
Publication number: 20200299400Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: May 24, 2018Publication date: September 24, 2020Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL